Details for Patent: 7,741,269

« Back to Dashboard

Summary for Patent: 7,741,269

Title:	Exendins and exendin agonists for weight reduction and obesity
Abstract:	Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
Inventor(s):	Andrew A. Young, Sunil Bhavsar, Bronislava Gedulin
Assignee:	Amylin Pharmaceuticals LLC
Application Number:	US10/895,909
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,741,269
Patent Claim Types: see list of patent claims	Use;

United States Patent 7,741,269: Exendin-4 Weight-Loss Claims, Scope, Expiration, and Patent Landscape

U.S. Patent No. 7,741,269 covers methods of reducing body weight or treating obesity by administering exendin-4, exendin peptides, or specified exendin agonist analogs. The broadest claims focus on the therapeutic use of the peptide class. Claims 43 and 44 are narrower and commercially more significant because they require subcutaneous administration of exendin-4 at a defined weight-based dose.

The patent was issued to Amylin Pharmaceuticals and reached the end of its ordinary U.S. patent term in 2021. It does not provide current U.S. exclusivity for exenatide obesity products. Its claims also do not cover semaglutide, liraglutide, dulaglutide, tirzepatide, or other non-exendin GLP-1 medicines.

What does U.S. Patent 7,741,269 protect?

The patent protects treatment methods, not the exendin-4 molecule as a composition of matter. A potential infringement case would therefore require proof that a party performs, induces, or contributes to a claimed method of treatment.

Claim group	Core subject matter	Principal limitation
Claims 1-9	Weight reduction using exendin-4	SEQ ID NO: 2 in claim 1; dose and combination limitations in dependent claims
Claims 10-21	Weight reduction using exendin peptides or agonist analogs	Broader sequence coverage, including SEQ ID NOs 1-188
Claims 22-30	Treatment of obesity using exendin-4	SEQ ID NO: 2 in claim 22
Claims 31-42	Treatment of obesity using exendin peptides or agonist analogs	Broad sequence and dosing alternatives
Claim 43	Weight reduction using subcutaneous exendin-4	0.1 to 10 μg/kg/day
Claim 44	Obesity treatment using subcutaneous exendin-4	0.1 to 10 μg/kg/day

The independent claims contain four recurring elements:

1. A human in need of weight reduction or obesity treatment.
2. Administration of exendin-4, an exendin peptide, or an exendin agonist analog.
3. A therapeutically effective amount.
4. Reduction in body weight or treatment of obesity.

The claims use “comprising,” which generally leaves the method open to additional steps or co-administered agents. A method can therefore include diet counseling, metformin, insulin, pramlintide, or another weight-loss treatment without necessarily falling outside the claim.

What is the scope of the exendin-4 sequence claims?

Claims 1, 22, 43, and 44 require an exendin-4 peptide comprising the amino acid sequence of SEQ ID NO: 2. On the supplied claim language, these are sequence-specific claims.

Claims 10-21 and 31-42 are broader in structure. They cover:

• Exendin peptides;
• Exendin agonist analog peptides;
• SEQ ID NOs 1 and 2;
• SEQ ID NOs 3, 4, and 5;
• SEQ ID NOs 6, 7, 8, 9, 40, and 41;
• SEQ ID NOs 10-39 and 42-188.

The practical boundary is the patent’s definition of “exendin agonist analog peptide,” the identity of each listed sequence, and the specification’s disclosure of functional activity. A peptide is not automatically within the claims merely because it activates the GLP-1 receptor. A non-exendin GLP-1 analog would generally require a separate claim-construction analysis.

Does the patent cover exenatide?

Yes, the claims directed to SEQ ID NO: 2 are directed to the exendin-4 peptide used as exenatide, assuming SEQ ID NO: 2 corresponds to the claimed exendin-4 sequence identified in the patent.

The patent claims the use of exenatide for weight reduction and obesity. It does not claim every therapeutic use of exenatide. A diabetes-treatment use, for example, would not satisfy the weight-reduction or obesity-treatment limitation unless the facts also establish the claimed result.

Does the patent cover semaglutide, liraglutide, or tirzepatide?

No, not as such.

Semaglutide, liraglutide, dulaglutide, and tirzepatide are structurally distinct molecules and are protected by separate patent estates. They are not exendin-4 merely because they act on the GLP-1 receptor. The patent’s sequence lists and analog definitions would need to be shown to encompass a particular peptide before a credible infringement theory could be advanced.

How do the dose and administration claims operate?

Claims 2 and 23 specify a daily dose of 10 μg to 1 mg. Claims 15 and 36 expand the range to 10 μg to 5 mg per day.

Claims 3 and 24 specify 0.1 to 10 μg/kg/day. Claims 16 and 37 specify 0.1 to 100 μg/kg/day. The word “human” appearing before the range in claims 16 and 37 appears to be a drafting error or transcription artifact. It does not create a meaningful additional therapeutic limitation.

Claims 4-6 and 17-18 cover broad administration routes, including:

• Intravenous administration;
• Intraperitoneal administration;
• Subcutaneous administration;
• Intramuscular administration;
• Oral administration;
• Topical, transmucosal, and transdermal administration;
• Nasal administration;
• Pulmonary inhalation.

“Peripheral injection” in claims 5, 17, 26, and 38 is broader than subcutaneous injection. Claims 43 and 44 are narrower because they require both subcutaneous administration and the 0.1 to 10 μg/kg/day dose range.

Which claims are commercially strongest?

Claims 43 and 44 are the most commercially focused claims because they align closely with the conventional delivery of exenatide.

Claim	Product-relevant requirement	Commercial assessment
1	Exendin-4, any listed therapeutic route, weight reduction	Broad method claim, but result and sequence must be established
10	Exendin peptide or analog, broad dose and route	Broadest functional class claim
22	Exendin-4 for obesity	Strong disease-specific claim
31	Exendin peptide or analog for obesity	Broad obesity-treatment claim
43	Subcutaneous exendin-4, 0.1-10 μg/kg/day	Narrow but closely aligned with injectable use
44	Subcutaneous exendin-4, 0.1-10 μg/kg/day for obesity	Narrowest and most product-specific claim

The dependent combination claims covering pramlintide, amylin agonists, leptin, calcitonin, cholecystokinin, or another weight-loss compound would require evidence that both the exendin therapy and the additional therapy are administered as part of the claimed method.

What is the patent expiration date?

U.S. Patent No. 7,741,269 was issued on June 22, 2010. Its ordinary patent term ended in 2021 based on the applicable twenty-year term measured from the relevant nonprovisional filing date. Public patent records identify the patent as expired or past its enforceable term.

Event	Date or status
Patent	U.S. 7,741,269
Patent holder at issuance	Amylin Pharmaceuticals
Issue date	June 22, 2010
Technology	Exendin-4 and exendin analog treatment of obesity and weight gain
Ordinary U.S. term	Ended in 2021
Current blocking value	No continuing U.S. patent exclusivity based on this patent

Any patent-term adjustment or terminal-disclaimer information must be taken from the USPTO patent record. Nothing in the supplied claims indicates a later effective term.

What is the FDA and Orange Book status?

Exenatide is FDA-approved for glycemic control in adults with type 2 diabetes, including the Byetta and Bydureon products. It is not approved in the United States as a chronic obesity-treatment product. The obesity claims in Patent 7,741,269 therefore concern a use that is distinct from the approved diabetes indication.

The Orange Book lists patents associated with FDA-approved drug products and approved uses. A method-of-use patent directed to obesity does not ordinarily create an Orange Book barrier for a diabetes-only exenatide label unless the patent is properly listed as covering an approved use. The patent’s obesity claims should not be treated as an automatic Orange Book prohibition against a diabetes-label generic.

Regulatory issue	Assessment
Exenatide FDA approval	Yes, for type 2 diabetes
FDA approval for obesity	No
Obesity indication in the exenatide label	No
Orange Book impact of obesity-only claims	Limited unless tied to an approved listed use
Biosimilar pathway	Not applicable; exenatide is a peptide drug, not a biologic approved under the biosimilar pathway
Likely generic pathway	ANDA or other small-molecule drug pathway, depending on product and reference listing

The absence of an obesity indication also weakens a practical infringement theory against a generic manufacturer that markets exenatide only for the approved diabetes indication. A plaintiff would need to establish induced infringement, label language, promotional conduct, or another factual basis connecting the product to the claimed obesity use.

Were there Paragraph IV challenges or patent litigation?

The principal commercial patent disputes involving Byetta and Bydureon concerned the broader exenatide product and formulation patent estate, including patents covering drug composition, sustained-release microspheres, manufacturing, and approved diabetes uses. Patent 7,741,269 is a separate obesity method patent.

Because the patent’s term ended in 2021, it does not present a current Paragraph IV launch barrier. A Paragraph IV notice directed to an unexpired listed patent could create Hatch-Waxman litigation and a potential 30-month stay. That mechanism has no continuing effect once the relevant patent has expired.

No current injunction or enforceable exclusionary right should be inferred from Patent 7,741,269. Historical litigation involving Amylin, Eli Lilly, AstraZeneca, Teva, or other exenatide participants must be matched to the specific patent asserted. Litigation concerning another Byetta or Bydureon patent does not establish that Patent 7,741,269 was asserted or remains enforceable.

How strong is the patent estate for exenatide obesity treatment?

The patent was commercially important when unexpired because it targeted a high-value use of exendin-4 that was not limited to glycemic control. Its strength had four components:

• Broad functional claims to exendin peptides and analogs;
• Specific claims to exendin-4;
• Dose ranges consistent with injectable exenatide use;
• Express obesity and body-weight endpoints.

Its current strength is substantially lower because the patent term has expired. The remaining IP risks for an exenatide obesity product would more likely arise from:

• Later formulation patents;
• Sustained-release delivery systems;
• Device patents;
• Manufacturing processes;
• Trade secrets;
• Regulatory exclusivity;
• Patents covering a different exendin analog or combination.

Patent 7,741,269 does not itself create a continuing manufacturing barrier. It is a method patent and does not, on the supplied claims, claim a production process, injectable formulation, device, or sustained-release microsphere.

How does this patent compare with competing GLP-1 patent estates?

Product	Active ingredient	Relationship to U.S. 7,741,269
Byetta	Exenatide	Directly relevant to SEQ ID NO: 2 claims
Bydureon	Extended-release exenatide	Directly relevant to exenatide use, but separate formulation and delivery patents may apply
Victoza/Saxenda	Liraglutide	Outside the patent’s ordinary exendin-4 scope
Trulicity	Dulaglutide	Separate GLP-1 analog estate
Ozempic/Wegovy	Semaglutide	Separate semaglutide composition, formulation, and use estate
Mounjaro/Zepbound	Tirzepatide	Separate dual GIP/GLP-1 agonist estate

The patent is therefore narrow at the molecular-class level but broad within exendin-based obesity treatment. It does not threaten competing GLP-1 medicines that use different peptide scaffolds.

What generic launch risks exist?

For a current exenatide product, Patent 7,741,269 presents no meaningful term-based launch risk in the United States. A generic manufacturer would instead evaluate:

1. Remaining Orange Book-listed patents for the reference product;
2. Formulation and extended-release delivery patents;
3. Device and cartridge patents;
4. Manufacturing and process patents;
5. Labeling and induced-infringement exposure;
6. State-law and commercial confidentiality issues.

A generic exenatide product marketed only for type 2 diabetes would have a weaker exposure profile under the obesity claims than a product labeled, promoted, or clinically positioned for weight loss.

Key Takeaways

• U.S. Patent 7,741,269 covers methods of using exendin-4 and related exendin peptides to reduce body weight or treat obesity.
• Claims 1, 22, 43, and 44 specifically target exendin-4 corresponding to SEQ ID NO: 2.
• Claims 10-21 and 31-42 extend to numerous exendin agonist analog sequences.
• Claims 43 and 44 require subcutaneous administration at 0.1 to 10 μg/kg/day.
• The patent does not cover semaglutide, liraglutide, dulaglutide, or tirzepatide as such.
• Exenatide is FDA-approved for type 2 diabetes, not obesity.
• The patent’s ordinary U.S. term ended in 2021.
• Current commercial risk is more likely to arise from formulation, delivery-device, manufacturing, or other exenatide patents than from U.S. 7,741,269.
• The patent is not a current standalone barrier to generic exenatide launch.

FAQs

Does Patent 7,741,269 cover off-label use of Byetta for weight loss?

Its claims are directed to administration of exendin-4 for weight reduction or obesity treatment. Off-label use could fall within the claim language, but enforcement would require facts showing performance or inducement of the claimed method.

Does the patent cover once-weekly exenatide?

Potentially, if the product uses the claimed exendin-4 sequence and the administration regimen falls within the claimed therapeutic method. Separate sustained-release formulation and delivery patents require independent review.

Is exendin-4 the same as exenatide?

Exenatide is the drug product based on exendin-4. The precise sequence, terminal modifications, formulation, and product presentation must be compared with the patent’s sequence definitions.

Can an exenatide generic avoid the patent by using a diabetes-only label?

Because the patent has expired, label design is no longer needed to avoid this patent as a term-based barrier. For historical analysis, a diabetes-only label would have reduced exposure to the obesity method claims unless other facts supported induced infringement.

Does the patent create biosimilar risk for GLP-1 products?

No. The patent does not create a biosimilar risk for semaglutide, liraglutide, dulaglutide, or tirzepatide. Those products have separate patent and regulatory frameworks.

References

1. U.S. Patent and Trademark Office. (2010). U.S. Patent No. 7,741,269: Methods of treating obesity using exendin-4.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2023). Byetta (exenatide) prescribing information.
4. U.S. Food and Drug Administration. (2023). Bydureon BCise (exenatide extended-release) prescribing information.
5. 35 U.S.C. § 154. (2024). Contents and term of patent; provisional rights.
6. 21 U.S.C. § 355. (2024). New drugs and abbreviated applications.

Drugs Protected by US Patent 7,741,269

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 7,741,269

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0996459		CA 2007 00034	Denmark
European Patent Office	0996459		91342	Luxembourg
European Patent Office	0996459		C00996459/01	Switzerland
European Patent Office	0996459		0790031-9	Sweden